News
October 2, 2026
Data obtained by APY Therapeutics show that APY-GNGPs exhibit in vivo efficacy in treatment of mouse lung infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
September 29, 2026
PCT patent application PCT/US24/61654 (filed December 23, 2024) by APY Therapeutics Founder and CEO Richard H. Ebright entered the national phase in China and published as Chinese patent application CN122847316. The patent application discloses the subclass of APY-GNGPs from which APY Therapeutics will choose its development candidate and backup.
July 9, 2025
APY Therapeutics is pleased to announce it has received a Catalyst Research and Development Voucher Award from the New Jersey Commission on Science, Innovation, and Technology. The award will fund mouse MRSA lung infection dose-escalation efficacy studies of APY-GNGPs for candidate selection.
July 3, 2025
PCT patent application PCT/US24/61654 (filed December 26, 2024) by APY Therapeutics Founder and CEO Richard H. Ebright published as WO/2025/144774. The patent application discloses the subclass of APY-GNGPs from which APY Therapeutics will choose its development candidate and backup.
June 2, 2025
APY Therapeutics is pleased to announce it has received a Stage I award from INCATE (INCubator for Antibacterial Therapies in Europe).
